Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors Woburn, MA

Appoints Veleka R. Peeples-Dyer to its Board of Directors

Woburn, MA, June 5, 2023 -

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed

oncolytic immunotherapies, today announced the appointment of Veleka R. Peeples-Dyer to the Company's Board of Directors effective

"We are pleased to welcome Veleka

to Replimune's Board of Directors," said Philip Astley-Sparke, Chief Executive Officer of Replimune. "Veleka is a highly

accomplished life sciences executive, experienced attorney and compliance professional with over 24 years of her practice dedicated to

the life sciences industry assisting with building legal and compliance teams and advising on the research, development, approval and

commercialization of products in the industry. We look forward to working with Veleka and believe her guidance and input will strengthen

our board as we advance and anticipate commercialization of our leading pipeline of oncolytic immunotherapies."

Ms. Peeples-Dyer has served as a strategic

enterprise leader at leading biopharmaceutical companies serving as in-house counsel for over 16 years and outside counsel to global

life sciences clients through her partnerships at prominent life sciences law firms, including as the Chair of the North American Food

and Drug practice and Co-Chair of the Global Regulatory Group at Baker McKenzie, a top ten global life sciences firm. Throughout her

career in the life sciences industry, including executive appointments as Chief Legal Officer, Chief Compliance Officer and Corporate

Secretary, Veleka has provided business, legal and compliance advice and counsel on a wide variety of matters, including Food and Drug

Administration (FDA) regulatory, global compliance, business development, clinical trials, quality, manufacturing, commercialization

and other corporate matters. Ms. Peeples-Dyer is currently on the Advisory Board of Syridex Bio, a life sciences impact investment firm

dedicated to the acceleration of health equity through focusing on investing in therapies for diseases that disproportionately affect

underserved populations.

Ms. Peeples-Dyer holds a Bachelor's

degree in Political Science from Hampton University and a Juris Doctor degree from the University of South Carolina School of Law. Veleka

is recognized across the legal and life sciences arena as a leader and has received numerous recognitions, including most recently being

named to The Top 50 Women Leaders of DC for 2023 and listed in Savoy Magazine as 2022 Most Influential Black Executives in Corporate

America, and 2022 Most Influential Black Lawyers.

Replimune Group, Inc., headquartered

in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed

oncolytic immunotherapies. Replimune's proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize

immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic

mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived

antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be

synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform

has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Forward Looking Statements

This press release contains forward

looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange

Act of 1934, as amended, including statements regarding the design and advancement of our clinical trials, the timing and sufficiency

of our clinical trial outcomes to support potential approval of any of our product candidates, our goals to develop and commercialize

our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, and other statements

identified by words such as "could," "expects," "intends," "may," "plans,"

"potential," "should," "will," "would," or similar expressions and the negatives of those

terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties,

many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking

statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results

for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory

approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product

candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health

issues, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and

other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described

in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required

by law, we undertake no obligation to update or revise these forward-looking statements.

Vice President, Corporate Communications